Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TSLP


Brief Information

Name:Thymic stromal lymphopoietin
Target Synonym:Thymic stromal lymphopoietin,TSLP
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

TSP-H52Hb-Cell-based assay

Response to human TSLP protein (Fold).
The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (AcroBiosystems, Cat. No. TSP-H52Hb). The max induction fold was approximately 45.15 (Routinely tested).


Captured Human TSLP (R127A, R130A) Protein, His Tag (Cat. No. TSP-H52Ha) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 4.22 nM as determined in SPR assay (Biacore T200) (Routinely tested).


Captured Human TSLP, His Tag (Cat. No. TSP-H52Hb) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 1.81 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Synonym Name



Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tezepelumab AMG-157; MEDI-9929 Approved Amgen Inc Tezspire Japan Asthma Astrazeneca Kk 2021-12-17 Eosinophilic Esophagitis; Dermatitis, Atopic; Hypersensitivity; Pulmonary Disease, Chronic Obstructive; Bronchial Diseases; Hypersensitivity, Immediate; Sinusitis; Respiratory Hypersensitivity; Asthma; Lung Diseases, Obstructive; Immune System Diseases; Lung Diseases; Respiratory Tract Diseases; Nasal Polyps; Nose Diseases; Chronic Urticaria; Anaphylaxis; Carcinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AZD-8630 AZD-8630; AMG-104 Astrazeneca Plc, Amgen Inc Details
BSI-045B BSI-045B Boaoxin Biotechnology(Nanjing) Co Ltd Details
SAR-443765 SAR-443765 Phase 1 Clinical Sanofi Inflammation Details
MK-8226 MK-8226 Merck & Co Inc Details
ASP-7266 UPB-101; ASP-7266 Phase 1 Clinical Astellas Pharma Inc, Upstream Biosciences Inc Asthma Details
QX-008N QX-008N; QX008N Phase 1 Clinical Qyuns Therapeutics Co Ltd Asthma Details
HBM-9378 SKB378; HBM-9378 Phase 1 Clinical Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Asthma Details
GR-1802 GR-1802 Phase 2 Clinical Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Asthma; Sinusitis; Dermatitis, Atopic Details
Ecleralimab CSJ-117; NOV-14 Phase 2 Clinical Novartis Pharma Ag Asthma; Pulmonary Disease, Chronic Obstructive Details
SHR-1905 SHR-1905 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Asthma Details
CM-326(Connaught Biomedical Technology) CM-326 Phase 2 Clinical Keymed Biosciences Co Ltd Nose Diseases; Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message